In a dose-ranging clinical study to evaluate the safety, efficacy and tolerability of five doses of Drug X compared with placebo in Type II diabetes patients with no prior exposure to anti-diabetic medication,Quintiles overcame a dropout rate of 42% to successfully recruit 420 patients a full month ahead of schedule.